GlassScriptPhysician profile
Joshua E Chan
NPI 1346828670
$740.87
in general payments reported to CMS, 2019-2025
12 companies · $724 in 2025
The $724 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $17.32 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $740.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $371.96 | 2025 | |
| Supernus Pharmaceuticals, INC. | $155.32 | 2025 | Qelbree |
| Dexcom, INC. | $41.12 | 2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $37.64 | 2024-2025 | Rexulti |
| Pfizer INC. | $34.91 | 2025 | |
| Lilly USA, LLC | $29.05 | 2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $16.17 | 2025 | Airsupra |
| Shield Therapeutics INC | $14.59 | 2025 | |
| Vanda Pharmaceuticals INC. | $14.43 | 2025 | Hetlioz, Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.81 | 2025 | Caplyta |
| Abbott Laboratories | $8.77 | 2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $3.10 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.